<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01856478</url>
  </required_header>
  <id_info>
    <org_study_id>1200.161</org_study_id>
    <secondary_id>1200-0161</secondary_id>
    <nct_id>NCT01856478</nct_id>
  </id_info>
  <brief_title>LUX-Head&amp;Neck 3: Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy</brief_title>
  <official_title>A Randomised, Open-label, Phase III Study to Evaluate the Efficacy and Safety of Oral Afatinib (BIBW 2992) Versus Intravenous Methotrexate in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Who Have Progressed After Platinum-based Therapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      This randomized, open-label, phase III study will be performed in patients with recurrent&#xD;
      and/or metastatic head and neck cancer which has progressed after platinum-based therapy. The&#xD;
      objectives of this trial are to compare the efficacy and safety of afatinib versus&#xD;
      methotrexate.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 23, 2013</start_date>
  <completion_date type="Anticipated">April 30, 2022</completion_date>
  <primary_completion_date type="Actual">August 22, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression free survival (PFS), defined as the time from the date of randomization to the date of progression evaluated according to RECIST 1.1 or to the date of death, whichever occurs first</measure>
    <time_frame>up to 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS), defined as the time from the date of randomization to the date of death (regardless of the cause of death)</measure>
    <time_frame>up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response defined as complete response (CR) or partial response (PR) determined by RECIST 1.1 according to the best response to study medication</measure>
    <time_frame>up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life (HRQOL) will be assessed based on patient-reported questionaires</measure>
    <time_frame>up to 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">340</enrollment>
  <condition>Head and Neck Neoplasms</condition>
  <arm_group>
    <arm_group_label>afatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral intake, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>methotrexate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intravenous bolus injection, once weekly</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <description>intravenous bolus injection, once weekly</description>
    <arm_group_label>methotrexate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>afatinib</intervention_name>
    <description>oral intake, once daily</description>
    <arm_group_label>afatinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed squamous cell carcinoma of the oral cavity,&#xD;
             oropharynx, hypopharynx or larynx, which has recurred/metastasised and is not amenable&#xD;
             for salvage surgery or radiotherapy.&#xD;
&#xD;
          -  Documented progressive disease based on investigator assessment according to RECIST,&#xD;
             following receipt of a cisplatin and/or carboplatin and/or Nedaplatin based regimen&#xD;
             administered for recurrent and/or metastatic disease independent of whether patient&#xD;
             progressed during or after platinum based therapy.&#xD;
&#xD;
          -  Measurable disease according to RECIST (version 1.1).&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 at Visit 2.&#xD;
&#xD;
          -  Male and female patients age is 18 years or older&#xD;
&#xD;
          -  Signed and dated written informed consent that is in compliance with ICH-GCP and local&#xD;
             law.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Progressive disease within three months after completion of curatively intended&#xD;
             treatment for locoregionally advanced or for metastatic head and neck squamous cell&#xD;
             cancer (HNSCC).&#xD;
&#xD;
          -  Primary tumour site nasopharynx (of any histology), sinuses, and/or salivary glands.&#xD;
&#xD;
          -  Any other than one previous platinum based systemic regimen given for recurrent and/or&#xD;
             metastatic disease, with the exception of immunotherapy used either before or after&#xD;
             platinum based treatment. Re-challenge with the platinum based regimen after a&#xD;
             temporary break is considered an additional line regimen only in case of progression&#xD;
             within the break.&#xD;
&#xD;
          -  Prior treatment with EGFR-targeted small molecules.&#xD;
&#xD;
          -  Treatment with any investigational drug less than four weeks or anti-cancer therapy&#xD;
             less than three weeks prior to randomization (except palliative radiotherapy to bones&#xD;
             to alleviate pain).&#xD;
&#xD;
          -  Unresolved chronic toxicity, other than hearing loss, tinnitus or dry mouth, CTCAE&#xD;
             grade &gt;2 from previous anti-cancer therapy or unresolved skin toxicities CTCAE grade&#xD;
             &gt;1 and/or diarrhoea CTCAE grade &gt;1 caused by prior treatment with EGFR targeted&#xD;
             antibodies.&#xD;
&#xD;
          -  Previous tumour bleeding CTCAE grade =3.&#xD;
&#xD;
          -  Requirement for treatment with any of the prohibited concomitant medications.&#xD;
&#xD;
          -  Major surgical or planned procedure less than four weeks prior to randomization&#xD;
             (isolated biopsies are not considered as major surgical procedures).&#xD;
&#xD;
          -  Any other malignancy unless free of disease for at least five years except for:&#xD;
&#xD;
               -  Other HNSCC of a location as described in inclusion criterion number 1&#xD;
&#xD;
               -  Appropriately treated superficial basal cell skin cancer&#xD;
&#xD;
               -  Surgically cured cervical cancer in situ&#xD;
&#xD;
               -  For Korea: endoscopically cured superficial esophageal and/or gastric cancer is&#xD;
                  allowed&#xD;
&#xD;
          -  Known lesion or signs of brain metastasis.&#xD;
&#xD;
          -  Known pre-existing interstitial lung disease (ILD).&#xD;
&#xD;
          -  Clinically relevant cardiovascular abnormalities, as judged by the investigator, such&#xD;
             as, but not limited to, uncontrolled hypertension, congestive heart failure NYHA&#xD;
             classification =III, unstable angina, myocardial infarction within six months prior to&#xD;
             randomization, or poorly controlled arrhythmia.&#xD;
&#xD;
          -  Significant or recent acute gastrointestinal disorders with diarrhoea as a major&#xD;
             symptom in the opinion of the investigator, e.g. Crohn's disease, malabsorption or&#xD;
             CTCAE grade &gt;1 diarrhoea of any aetiology at randomization.&#xD;
&#xD;
          -  Known HIV, active hepatitis B, active hepatitis C, and/or other known severe&#xD;
             infections, including but not limited to tuberculosis, as judged by the investigator.&#xD;
&#xD;
          -  Other significant disease that in the investigator's opinion would exclude the subject&#xD;
             from the trial.&#xD;
&#xD;
          -  Screening laboratory values:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) &lt;1.5x10^9/l&#xD;
&#xD;
               -  Platelet count &lt;75x10^9/l&#xD;
&#xD;
               -  Total bilirubin &gt;1.5 times the upper limit of normal (ULN)&#xD;
&#xD;
               -  Aspartate amino transferase (AST) or alanine amino transferase (ALT) &gt;3 times the&#xD;
                  ULN (if related to liver metastases &gt;5 times the ULN)&#xD;
&#xD;
               -  Calculated creatinine clearance &lt;50 ml/min (as evidenced by using the&#xD;
                  Cockcroft-Gault formula).&#xD;
&#xD;
          -  Women of child-bearing potential and men who are able to father a child, unwilling to&#xD;
             be abstinent or to use adequate contraception during the trial and for at least six&#xD;
             months after end of treatment. Adequate methods of contraception and definition of&#xD;
             child-bearing potential.&#xD;
&#xD;
          -  Pregnancy or breast feeding.&#xD;
&#xD;
          -  Known or suspected hypersensitivity to any of the study medications or their&#xD;
             excipients.&#xD;
&#xD;
          -  Patients unable to comply with the protocol, in the opinion of the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing Chao-Yang Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital of Chinese Academy of Medical Science</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Navy General Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Affiliated toumor hospital of bengbu medical college</name>
      <address>
        <city>Bengbu</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second People's Hospital of Sichuan</name>
      <address>
        <city>Chengdu</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West China Hospital</name>
      <address>
        <city>Chengdu</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sun Yat-Sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Third Affiliated Hospital of Harbin Medical University</name>
      <address>
        <city>Haerbin</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>the 81th Hospital of PLA</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renji Hospital Shanghai Jiaotong Univesrity School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Changzheng Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Ninth People's Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tongji Hospital, Tongji University</name>
      <address>
        <city>Wuhan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wuhan Union Hospital</name>
      <address>
        <city>Wuhan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alexandria University Hospital</name>
      <address>
        <city>Alexandria</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute, Cairo University</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mansoura University Faculty of Medicine</name>
      <address>
        <city>Dakahlia</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pamela Youde Nethersole Eastern Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hongkong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Shatin</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sujan Surgical Cancer Hospital</name>
      <address>
        <city>Amravati</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pristine Hospital</name>
      <address>
        <city>Bengaluru</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Acharya Tulsi Regional Cancer Treatment and Research Institute</name>
      <address>
        <city>Bikaner</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rajiv Gandhi Government General Hospital</name>
      <address>
        <city>Chennai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M N J Institute of Oncology and Regional Cancer Centre</name>
      <address>
        <city>Hyderabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geetanjali Medical College and Hospital</name>
      <address>
        <city>Jaipur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>J K Cancer Institute</name>
      <address>
        <city>Kanpur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>B. P .Poddar Hospital and Medical Research Ltd.</name>
      <address>
        <city>Kolkata, West Bengal</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King George Medical University</name>
      <address>
        <city>Lucknow</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Government Medical College and Hospital</name>
      <address>
        <city>Nagpur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shatabdi Hospital, Nashik</name>
      <address>
        <city>Nasik</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Noble Hospital Pvt Ltd</name>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruby Hall Clinic</name>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Goyang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Seoul St.Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Perpetual Succour Hospital (Cebu)</name>
      <address>
        <city>Cebu City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Medical Center</name>
      <address>
        <city>Quezon City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keelung Chang Gung Memorial Lover's Lake Branch</name>
      <address>
        <city>Keelung City</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tri-Service General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maharaj Nakom Chiangmai Hospital</name>
      <address>
        <city>Chiang Mai</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Srinagarind Hospital</name>
      <address>
        <city>Muang</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Naresuan University Hospital</name>
      <address>
        <city>Phitsanulok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Songklanagarind Hospital</name>
      <address>
        <city>Songkla</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>Egypt</country>
    <country>Hong Kong</country>
    <country>India</country>
    <country>Korea, Republic of</country>
    <country>Philippines</country>
    <country>Taiwan</country>
    <country>Thailand</country>
  </location_countries>
  <link>
    <url>https://www.mystudywindow.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 15, 2013</study_first_submitted>
  <study_first_submitted_qc>May 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2013</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Afatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed &quot;Document Sharing Agreement&quot;.&#xD;
Also, Researchers can use the following link https://www.mystudywindow.com/msw/datasharing to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.&#xD;
The data shared are the raw clinical study data sets.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.</ipd_time_frame>
    <ipd_access_criteria>For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.</ipd_access_criteria>
    <ipd_url>https://www.mystudywindow.com/msw/datasharing</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

